Pharmacotherapy for the prevention of post-ERCP pancreatitis.
Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.
Foster
Erina
E
Leung
Joseph
J
D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D010195:Pancreatitis / Q000209:etiology* / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
D005765:Gastrointestinal Agents; D015282:Octreotide